首页> 美国卫生研究院文献>AAPS PharmSciTech >Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of andersen 8-stage cascade impactor next generation pharmaceutical impactor and model 3321 aerodynamic particle sizer aerosol spectrometer
【2h】

Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: Comparison of andersen 8-stage cascade impactor next generation pharmaceutical impactor and model 3321 aerodynamic particle sizer aerosol spectrometer

机译:加压定量吸入器气雾剂的空气动力学粒度分析:安徒生8级级联撞击器下一代药物撞击器和3321型空气动力学粒度仪气溶胶光谱仪的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The purpose of this research was to compare three different methods for the aerodynamic assessment of (1) chloroflurocarbon (CFC)-fluticasone propionate (Flovent), (2) CFC-sodium cromoglycate (Intal), and (3) hydrofluoroalkane (HFA)-beclomethasone dipropionate (Qvar) delivered by pressurized metered dose inhaler. Particle size distributions were compared determining mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction <4.7 μm aerodynamic diameter (FPF<4.7 μm). Next Generation Pharmaceutical Impactor (NGI)-size distributions for Flovent comprised finer particles than determined by Andersen 8-stage impactor (ACI) (MMAD=2.0±0.05 μm [NGI]; 2.8±0.07 μm [ACI]); however FPF<4.7 μm by both impactors was in the narrow range 88% to 93%. Size distribution agreement for Intal was better (MMAD=4.3±0.19 μm (NGI), 4.2±0.13 μm (ACI), with FPF<4.7 μm ranging from 52% to 60%. The Aerodynamic Particle Sizer (APS) undersized aerosols produced with either formulation (MMAD=1.8±0.07 μm and 3.2±0.02 μm for Flovent and Intal, respectively), but values of FPF<4.7 μm from the single-stage impactor (SSI) located at the inlet to the APS (82.9%±2.1% [Flovent], 46.4%±2.4% [Intal]) were fairly close to corresponding data from the multi-stage impactors. APS-measured size distributions for Qvar (MMAD=1.0±0.03 μm; FPF<4.7 μm=96.4% ±2.5%), were in fair agreement with both NGI (MMAD=0.9±0.03 μm; FPF<4.7 μm=96.7%±0.7%), and ACI (MMAD=1.2±0.02 μm, FPF<4.7 μm=98%±0.5%), but FPF<4.7 μm from the SSI (67.1%±4.1%) was lower than expected, based on equivalent data obtained by the other techniques. Particle bounce, incomplete evaporation of volatile constituents and the presence of surfactant particles are factors that may be responsible for discrepancies between the techniques.
机译:这项研究的目的是比较三种不同的空气动力学评估方法:(1)氯氟烃(CFC)-丙酸氟替卡松(Flovent),(2)CFC-色甘酸钠(Intal)和(3)氢氟烷烃(HFA)-加压定量吸入器输送倍氯米松双丙酸酯(Qvar)。比较粒径分布,确定质量中位数空气动力学直径(MMAD),几何标准偏差(GSD)和<4.7μm空气动力学直径的细颗粒分数(FPF <4.7μm)。 Flovent的下一代药物撞击器(NGI)尺寸分布比安德森8级撞击器(ACI)确定的颗粒更细(MMAD = 2.0±0.05μm[NGI]; 2.8±0.07μm[ACI]);但是,两个撞击器的FPF <4.7μm都在88%至93%的狭窄范围内。 Intal的尺寸分布一致性更好(MMAD = 4.3±0.19μm(NGI),4.2±0.13μm(ACI),FPF <4.7μm在52%至60%之间。两种配方(Flovent和Intal的MMAD分别为1.8±0.07μm和3.2±0.02μm),但来自位于APS入口的单级撞击器(SSI)的FPF值<4.7μm(82.9%±2.1) %[Flovent],46.4%±2.4%[Intal])与多级冲击器的相应数据相当接近,APS测量的Qvar尺寸分布(MMAD = 1.0±0.03μm; FPF <4.7μm= 96.4%± 2.5%)与NGI(MMAD = 0.9±0.03μm; FPF <4.7μm= 96.7%±0.7%)和ACI(MMAD = 1.2±0.02μm,FPF <4.7μm= 98%±0.5)都完全一致%),但根据其他技术获得的等效数据,来自SSI的FPF <4.7μm(67.1%±4.1%)低于预期,颗粒反弹,挥发性成分蒸发不完全和表面活性剂颗粒的存在是可能导致差异技术之间的联系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号